SLC5A2 and infection: Overall, the risk of mycotic genital infections was 3.54-times higher among those allocated an SGLT-2 inhibitor compared to placebo (3.54, 3.11-4.03; 1837 events), but these infections rarely led to severe complications and there were too few cases of Fournier's gangrene to estimate RRs reliably (Supplemental Figure 9).